Table 3.
Investigator-assessed response per RECIST
| Osimertinib-relapsed (n = 45) | |
|---|---|
| ORRa (95% CI) | 36% (22–51) |
| CBRb (95% CI) | 64% (49–78) |
| Best response, n (%) | |
| CR | 1 (2) |
| PR | 15 (33) |
| SD | 14 (31) |
| PD | 11 (24) |
| NE | 4 (9) |
| mDOR, months (95% CI) | 9.6 (5.3–NC) |
| mPFS, months (95% CI) | 4.9 (3.7–9.5) |
| mOS, months (95% CI) | NC |
aProportion of patients who had CRs or PRs.
bProportion of patients who had CRs or PRs or SD for ≥11 weeks (corresponding to two disease assessments).
mDOR, median duration of response; mOS, median overall survival; mPFS, median progression-free survival; NE, not evaluable.